Skip to main content
Adithya Cattamanchi, MD, Pulmonology, Orange, CA

Adithya Cattamanchi MD

Pulmonology•Orange, CA

Critical Care Medicine

Professor of Medicine and Chief, Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine

Join to View Full Profile

  • 101 The City Drive SouthOrange, CA 92868

  • Phone+1 714-456-2959

  • Fax+1 714-456-3597

Dr. Cattamanchi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Cattamanchi's Full ProfileAlready have an account?

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2003 - 2005
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2005 - 2026
  • Pulmonary Disease
    American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Rapid Molecular Testing with Duration of Respiratory Isolation for Patients with Possible Tuberculosis in a US Hospital  
    Barbara Haller, Adithya Cattamanchi, Julie Higashi, JAMA

Press Mentions

  • BRAF Mutation in Non-Small Cell Lung Cancer: Your FAQs Answered
    BRAF Mutation in Non-Small Cell Lung Cancer: Your FAQs AnsweredMarch 7th, 2025
  • The Fight Against TB Was Frozen in Time, Until Now. See Its Future
    The Fight Against TB Was Frozen in Time, Until Now. See Its FutureMarch 4th, 2025
  • Congratulations to Mulago Hospital’s Dr William Worodria
    Congratulations to Mulago Hospital’s Dr William WorodriaMay 17th, 2023
  • Join now to see all

Grant Support

  • Partnerships for Research in Implementation Science for Equity in Heart and Lung diseases training program (PRISE-HL T32)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
  • Partnerships for Research in Implementation Science for Equity in Heart and Lung diseases training program (PRISE-HL T32)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
  • PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT studyUNIVERSITY OF CALIFORNIA-IRVINE2023–2028
  • Partnerships for Research in Implementation Science for Equity in Heart and Lung diseases training program (PRISE-HL T32)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
  • C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
  • C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
  • C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
  • C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
  • C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
  • Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settingsUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
  • Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settingsUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
  • Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settingsUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
  • Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
  • Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
  • Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
  • Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
  • Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options TrialUNIVERSITY OF CALIFORNIA-IRVINE2018–2025
  • Immunodiagnosis Of Active Tuberculosis In Hiv-Infected PatientsNational Heart, Lung, And Blood Institute2009–2012
  • TB Guidline Observation And Adherence In Low Income Countries (Tb Goal)National Institute Of Allergy And Infectious Diseases2011

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Adithya Cattamanchi, Dr. Adithya Cattamanchi, MD, Dr. A Cattamanchi